尽管在过去的十年中，在肺癌的肿瘤反应和患者存活方面取得了显著进展，但整体免疫治疗对肺癌的疗效仅能在大约一半的患者中产生明确的反应。基于这个限制，正在研究组合策略以提高治疗反应率。冷冻消融已被提出作为一种诱导免疫细胞死亡并与免疫检查点抑制剂等全身免疫治疗产生协同效应的技术之一。冷冻消融传统上是通过穿刺引导进行，然而最近的技术进展允许通过支气管镜传递。在本文中，我们回顾了冷冻消融在非小细胞肺癌中的临床前和临床证据，并探讨其潜在抗肿瘤免疫作用。我们重点介绍了涉及该方法的正在进行的研究，并提出了未来研究的方向。© 2023 Velez, DeMaio和Sterman的版权所有。

Despite remarkable advances in tumor response and patient survival in the past decade, systemic immunotherapies for lung cancer result in an objective response in only around half of patients treated. On the basis of this limitation, combination strategies are being investigated to improve response rates. Cryoablation has been proposed as one such technique to induce immunogenic cell death and synergize with systemic immunotherapies, including immune checkpoint inhibitors. Cryoablation has been traditionally delivered percutaneously with imaging guidance although recent technological advances allow for bronchoscopic delivery. Herein, we review the pre-clinical and clinical evidence for the use of cryoablation in non-small cell lung cancer and potential induction of anti-tumor immunity. We highlight ongoing studies involving this approach and propose areas of future investigation.Copyright © 2023 Velez, DeMaio and Sterman.